# Study to Assess Bronchospasm Potentially Induced by Next-Generation Propellant vs HFA Propellant in an MDI in Participants With Well/Partially Controlled Asthma

> **NCT05850494** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 52 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** HFA MDI
- **DRUG:** HFO MDI

## Key facts

- **NCT ID:** NCT05850494
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-02
- **Primary completion:** 2023-08-21
- **Final completion:** 2023-08-21
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05850494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05850494, "Study to Assess Bronchospasm Potentially Induced by Next-Generation Propellant vs HFA Propellant in an MDI in Participants With Well/Partially Controlled Asthma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05850494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*